Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-27 22:49:38 - browse：31193

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： STAT wants to know your pick for a great summer read or listen

WSS

White House pharmacy plagued with problems, investigation finds

Investment in vaccine development is lagging, report finds

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Investment in vaccine development is lagging, report finds

Venture capital firm's plans to take over Akron hospital face hurdles

FDA approves Moderna’s RSV vaccine, its second licensed product

leisure time

Wikipedia

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

Bernie Sanders is gearing up to subpoena pharma CEOs

How to save PrEP access — and even expand it

'Little Tech' descents on D.C., wanting a say in how AI is regulated

As demand for Covid shots wanes, Moderna seeks its next success

CMS got Medicare Advantage quality rating wrong, judge rules

Medical records are filled with copy

Senators tussle over abortion against the backdrop of a presidential campaign

Continuity nursing helped my family in our darkest PICU moments

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

focus

Bernie Sanders is gearing up to subpoena pharma CEOs

Medicare drug price negotiation legal challenge met with skepticism

STAT wants to know your pick for a great summer read or listen

Biogen walks away from Aduhelm, years after polarizing approval

How CO2 helps viruses stay alive longer in the air

Illumina board agrees to spin off Grail, as divestment plans proceed

focus

focus

focus

focus